Top 3 Picks
2026 Outlook
The Electromedical sector is projected to expand significantly by 2026, driven by a compound annual growth rate exceeding 10% as telemedicine and AI-integrated devices gain mainstream adoption, according to industry forecasts. Key trends include increasing regulatory approvals for innovative products and a shift towards personalized medicine, which could boost market penetration. However, challenges like supply chain volatility and stringent regulations may temper growth, making strategic investments in high-scoring companies essential.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
Fonar Corporation
|
67.9 | $18.52 | $103M |
|
2
|
Electromed, Inc.
|
65.4 | $27.39 | $206M |
|
3
|
Iridex Corp
|
64.9 | $1.17 | $19M |
|
4
|
Medtronic plc
|
61.0 | $96.05 | $121.6B |
|
5
|
CONMED Corporation
|
59.6 | $40.52 | $1.5B |
|
6
|
LivaNova PLC Ordinary Shares
|
57.5 | $60.64 | $2.8B |
|
7
|
Soleno Therapeutics, Inc. Common Stock
|
57.3 | $47.17 | $3.2B |
|
8
|
Streamex Corp. Common Stock
|
56.9 | $3.11 | $198M |
|
9
|
Vivani Medical, Inc. Common Stock (DE)
|
56.8 | $1.27 | $85M |
|
10
|
Precision Optics Corporation, Inc. Common Stock
|
56.7 | $4.25 | $33M |
|
11
|
Axogen, Inc. Common Stock
|
55.9 | $31.00 | $822M |
|
12
|
Integer Holdings Corporation
|
55.8 | $76.78 | $3.6B |
|
13
|
CapsoVision, Inc. Common Stock
|
55.6 | $10.24 | $220M |
|
14
|
Outset Medical, Inc. Common Stock
|
55.3 | $3.70 | $249M |
|
15
|
Masimo Corporation
|
54.4 | $127.40 | $7.7B |
In-Depth Analysis: Top Electromedical Stocks
FONR
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic …
Fonar Corporation stands out in the Electromedical sector as a key player in MRI technology, designing and manufacturing scanners that enable non-invasive detection and diagnosis of diseases, which is critical for advancing healthcare outcomes. Its focus on innovative MRI solutions addresses growing demands for precise medical imaging amid an aging population and increasing chronic disease prevalence.
Fonar's 7.1% profit margin indicates moderate profitability, reflecting efficient cost management in a competitive sector, while its 5.8% ROE suggests room for improvement in equity utilization to generate higher returns. With a 4.3% revenue growth rate and a P/E ratio of 13.3, the company demonstrates stable financial health and potential undervaluation compared to industry peers.
Fonar's steady 4.3% revenue growth positions it well for continued expansion in the electromedical market, driven by rising demand for advanced MRI diagnostics by 2026. The company's P/E ratio of 13.3 offers an attractive entry point for investors seeking undervalued stocks with a Tradestie Score of 67.9, indicating solid fundamentals. Furthermore, as healthcare technologies evolve, Fonar's specialized MRI expertise could lead to enhanced market share and profitability, making it a compelling buy for long-term gains.
ELMD
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and …
Electromed Inc. matters in the Electromedical sector due to its specialized focus on airway clearance therapies, such as the SmartVest system, which addresses critical respiratory needs for patients with compromised pulmonary function, enhancing patient outcomes in an aging population.
Electromed's 12.4% profit margin and 19.0% ROE indicate strong profitability and efficient use of equity, demonstrating financial health despite a P/E ratio of 30.7 that suggests growth expectations are priced in.
Electromed's 15.1% revenue growth positions it for continued expansion by 2026, driven by increasing demand for home-based respiratory therapies amid rising chronic conditions. The company's robust 19.0% ROE and Tradestie Score of 65.4 signal strong operational efficiency and market potential, making it an appealing investment for growth-oriented portfolios. Additionally, innovations like the SmartVest system could capture greater market share in the electromedical sector as healthcare trends shift toward personalized treatments.
IRIX
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It …
IRIDEX Corp matters in the Electromedical sector due to its focus on innovative laser-based medical systems for ophthalmology, addressing critical conditions like glaucoma and retinal disorders with products such as laser delivery devices and surgical instruments. This specialization positions the company to capitalize on the growing demand for minimally invasive eye care solutions, driven by an aging global population and advancements in medical technology.
IRIDEX's negative profit margin of -10.0% highlights ongoing operational losses, while a ROE of -139.3% indicates inefficient use of equity, signaling financial strain. However, the company's revenue growth of 7.8% demonstrates positive top-line expansion, which could improve profitability if cost management and market penetration efforts succeed.
IRIDEX's 7.8% revenue growth reflects increasing demand for its ophthalmology products, suggesting potential for market share gains in the expanding electromedical sector by 2026. The Tradestie Score of 64.9/100 indicates moderate investment viability, supported by ongoing innovations in laser technologies that could enhance competitiveness. As global eye care needs rise due to demographic shifts, IRIDEX is poised for a profitability turnaround, making it an attractive buy for investors seeking growth in medical devices.
MDT
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign …
Medtronic is a leading force in the Electromedical sector as one of the world's largest medical-device companies, specializing in innovative therapies for chronic diseases such as pacemakers, defibrillators, and insulin pumps, which address critical healthcare needs for millions globally.
Medtronic's 13.7% profit margin indicates strong operational efficiency in generating profits from revenue, while its 9.8% ROE demonstrates moderate returns on shareholder equity, supported by a 6.6% revenue growth that signals ongoing business expansion despite a P/E ratio of 26.2 suggesting a relatively high valuation.
Medtronic's steady 6.6% revenue growth, driven by its expansive portfolio in chronic disease management, positions the company for continued demand in an aging global population by 2026. The firm's innovative products like transcatheter heart valves and neurovascular devices are likely to benefit from advancing healthcare technologies and market penetration. With a Tradestie Score of 61.0, indicating a balanced investment opportunity, Medtronic offers potential for long-term capital appreciation amid sector growth.
CNMD
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is …
Conmed Corporation matters in the Electromedical sector due to its specialized focus on sports medicine procedures and general surgeries, providing essential equipment for specialties like orthopedics, gynecology, and thoracic surgery. Its products support improved surgical outcomes and efficiency for healthcare professionals, positioning it as a key player in advancing medical technology within this growing industry.
Conmed's profit margin of 4.8% indicates moderate profitability in a competitive sector, while its ROE of 6.6% suggests reasonable efficiency in utilizing shareholder equity. The 6.7% revenue growth reflects steady financial health, balanced by a P/E ratio of 20.1 that aligns with market expectations for sustainable earnings.
Investors should consider buying CNMD in 2026 given its 6.7% revenue growth, which signals ongoing expansion in the electromedical market driven by increasing demand for surgical equipment. The P/E ratio of 20.1 offers a reasonable valuation compared to peers, potentially leading to upside as the company capitalizes on trends in sports medicine and general surgery. Additionally, with a Tradestie Score of 59.6, it presents moderate investment potential amid sector recovery and innovation.
LIVN
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly …
LivaNova PLC matters in the Electromedical sector due to its specialized focus on cardiopulmonary solutions, such as heart-lung machines, and neuromodulation devices for treatment-resistant epilepsy and depression, addressing critical unmet needs in global healthcare. As a result of its merger between US-based Cyberonics and Italian Sorin, the company combines innovative technologies and international expertise, positioning it as a key player in advancing medical device solutions for complex conditions.
LivaNova's negative profit margin of -16.1% and ROE of -17.6% highlight ongoing challenges in profitability and inefficient equity utilization, indicating the company is currently operating at a loss despite its operations. However, the 12.5% revenue growth reflects strong top-line expansion, suggesting potential for financial recovery if operational efficiencies are achieved.
LivaNova's 12.5% revenue growth indicates robust demand for its neuromodulation and cardiopulmonary products, positioning the company for potential profitability by 2026 as it capitalizes on expanding markets for epilepsy and depression treatments. The Tradestie Score of 57.5 signals moderate upside potential, supported by the electromedical sector's growth driven by aging populations and technological advancements. Investors may find value in LivaNova's strategic innovations, which could lead to market share gains and stock appreciation in the coming years.
SLNO
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Soleno Therapeutics matters in the Electromedical sector as a biopharmaceutical innovator focusing on rare diseases, where its DCCR extended-release tablets could complement electromedical devices in delivering advanced treatments. This positions the company as a key contributor to personalized medicine, addressing unmet needs in rare disease management through proprietary formulations.
Soleno Therapeutics exhibits poor profitability with a profit margin of -79.5%, reflecting substantial operational losses likely driven by high R&D costs in biopharmaceutical development. Additionally, an ROE of -20.7% indicates inefficient use of shareholder equity, signaling financial strain common in early-stage companies awaiting product commercialization.
By 2026, investors should consider SLNO due to the potential FDA approval of DCCR, which has demonstrated efficacy in clinical trials for rare diseases, potentially driving revenue growth in a market expected to exceed $200 billion globally. The company's Tradestie Score of 57.3 suggests moderate upside potential, especially if DCCR captures significant market share in niche therapeutics. Furthermore, as biopharmaceutical advancements accelerate, Soleno's focus on innovative formulations could yield high returns if successful in late-stage trials and partnerships.
STEX
Streamex Corp is a Real World Asset (RWA) tokenization company with Institutional grade infrastructure to bring the gold and commodities market on chain. Enabled by a gold denominated treasury and tokenization technology powering the modern commodities market.
Streamex Corp matters in the Electromedical sector by leveraging its RWA tokenization technology to potentially tokenize medical equipment and supplies as commodities, enhancing liquidity and accessibility in a traditionally fragmented market. This infrastructure could streamline supply chain financing for electromedical devices, fostering innovation and efficiency in healthcare asset management.
With limited financial data available, Streamex's Tradestie Score of 56.9 out of 100 indicates moderate financial health, suggesting potential profitability from its tokenization services amid growing blockchain adoption, though this score reflects uncertainties in revenue stability.
By 2026, Streamex's gold-denominated treasury and tokenization platform are poised to capitalize on the projected 30% CAGR in the global blockchain market for commodities, potentially driving stock value through increased institutional adoption. The company's institutional-grade infrastructure could enable seamless on-chain trading of assets like electromedical equipment, positioning it for market leadership as regulatory frameworks evolve. Additionally, with a Tradestie Score of 56.9 signaling room for upside, investors may benefit from the expanding RWA ecosystem if Streamex executes its strategy effectively.
VANI
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and …
Vivani Medical matters in the Electromedical sector due to its proprietary NanoPortal technology, which develops miniaturized subdermal implants for long-term, near-constant-rate delivery of medicines to treat chronic diseases, potentially transforming patient adherence and outcomes in areas like diabetes and obesity management.
Vivani Medical's Return on Equity of -265.0% indicates severe financial strain, reflecting substantial losses relative to shareholders' equity and highlighting the challenges of a preclinical-stage biopharmaceutical company with high R&D costs. The Tradestie Score of 56.8/100 suggests moderate investment appeal, but this is undermined by the negative profitability, pointing to ongoing risks in achieving financial sustainability.
By 2026, Vivani's NanoPortal technology could advance to clinical success and regulatory approvals, enabling market entry for chronic disease treatments and potentially driving revenue growth through partnerships in the expanding electromedical market. The platform's ability to provide sustained drug delivery addresses key unmet needs, such as reducing injection frequency, which could capture significant market share estimated at billions in the biopharmaceutical sector. Despite the current -265.0% ROE, the company's innovative approach positions it for high upside if it achieves milestones like FDA filings in the next few years.
POCI
Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy …
Precision Optics Corp Inc matters in the Electromedical sector due to its expertise in designing and manufacturing advanced optical instruments like endoscopes and endocouplers, which are essential for minimally invasive surgical and diagnostic procedures amid rising demand for precise, less invasive medical technologies.
The company's negative profit margin of -28.3% and ROE of -58.0% indicate current unprofitability and inefficient equity utilization, highlighting financial challenges in achieving positive returns; however, a robust revenue growth of 59.2% suggests potential for improved financial health as operations scale and market adoption increases.
Precision Optics' 59.2% revenue growth demonstrates strong market traction in the electromedical sector, positioning the company for potential profitability by 2026 as demand for minimally invasive procedures continues to rise. The Tradestie Score of 56.7/100, while moderate, underscores a balanced risk-reward profile that could appeal to growth-oriented investors amid expanding optical technology applications. With ongoing advancements in medical optics, POCI is likely to capture greater market share, driving stock appreciation and making it a viable buy for long-term portfolios by 2026.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.